
    
      A Phase I, Single-centre, Open-label, Dose-escalation Study to Assess the Safety,
      Tolerability and Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) Given
      Orally in Japanese and Non-Japanese Asian Healthy Male Volunteers
    
  